The Use of Direct Acting Oral Anti-Coagulants in Vulnerable Populations
| Overview / Abstract: |
Recommendations and evidence surrounding the use of DOAC’s in special populations continue to evolve to address concerns of use in patients with obesity, renal disease, active malignancy, and older adults. DOAC’s are a widely prescribed newer class of medications with emerging clinical recommendations and evidence for safe use. Pharmacists have a key role to play as part of the care team in formulating anticoagulation regimens that are appropriate for individual patients, and would benefit from education on the efficacy and safety of DOAC’s in vulnerable populations. |
|
Expiration |
Sep 30, 2022 |
|
Discipline(s) |
Pharmacy CPE |
|
Format |
Online |
|
Credits / Hours |
2.0 |
|
Accreditation |
ACPE |
|
Presenters / Authors / Faculty |
Maya R. Chilbert (Holsen), PharmD, BCCP |
|
Activity Specialities / Related Topics |
Cardiology / Cardiovascular, Hematology, Oncology / Cancer / Radiation Therapy, Pharmacology |
|
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. |
|
Keywords / Search Terms |
American Academy of CME Oral Anti-Coagulants Vulnerable populations Medically ill direct acting oral anti-coagulants (DOAC’s) Pharmacy atrial fibrillation anticoagulation regimen Venous thromboembolism (VTE) Free CE CME |
|